Ad
related to: fda approved ovarian cancer drugs names list a-z free printablegotoper.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
Rucaparib: On December 19, 2016, the US FDA granted accelerated approval for previously treated BRCA-mutant ovarian cancer. [8] In April 2018 it was granted FDA approval. Niraparib: In March 2017 approved by US FDA for epithelial ovarian, fallopian tube, and primary peritoneal cancer. [9] [10] Inhibitor of PARP1 and PARP2. [11]
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
This is a list of chemotherapeutic agents, also known as cytotoxic agents or cytostatic drugs, that are known to be of use in chemotherapy for cancer.This list is organized by type of agent, although the subsections are not necessarily definitive and are subject to revision.
(Reuters) -The U.S. Food and Drug Administration said on Friday it had granted traditional approval for AbbVie's "guided missile" cancer therapy, Elahere, for patients with a type of ovarian ...
Small cell lung cancer, ovarian cancer and cervical cancer: Diarrhoea, myelosuppression, interstitial lung disease and allergy. 1.05 Anthracyclines: Daunorubicin: IV: Inhibits DNA and RNA synthesis by intercalating DNA base pairs. Inhibits DNA repair by inhibiting topoisomerase II. Acute leukaemias
In January 2018, olaparib was approved in the United States for the treatment of patients with certain types of breast cancer that have spread (metastasized) and whose tumors have a specific inherited (germline) genetic mutation, making it the first drug in its class (PARP inhibitor) approved to treat breast cancer, and it is the first time any ...
Treatment of adults with locally advanced, unresectable (stage III) non- small cell lung cancer (NSCLC) whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test [2] Repotrectinib
It was approved on 27 March 2017 in the US, [5] and approved in European Union on 16 November 2017. [15] In a study with 553 patients, progression-free survival (PFS) for patients with a deleterious or suspected deleterious BRCA mutation in the germline was 21.0 months under niraparib therapy, as compared to 5.5 months under placebo. Patients ...
Ad
related to: fda approved ovarian cancer drugs names list a-z free printablegotoper.com has been visited by 10K+ users in the past month